SOLVSolventum

Customers the company names as a large share of revenue or receivables (it must name any worth 10% of revenue).

“No customer accounted for more than 10% of the Company’s revenues for the years ended December 31, 2025, 2024, or 2023.”

Read it in the 10-K ↗

New “Additionally, no customers accounted for more than 10% of accounts receivable as of December 31, 2025 and 2024.”

Read it in the 10-K ↗

Parts or manufacturing that depend on one or a few suppliers.

“In addition, some of Solventum’s suppliers are limited- or sole-source suppliers, and Solventum’s ability to meet its obligations to customers depends on the performance, product quality and stability of such suppliers and Solventum’s ability to source alternatives in a cost effective manner.”

Read it in the 10-K ↗

“3M is the sole source of supply for raw materials used in certain of our products and our business will be harmed if 3M does not satisfy our requirements.”

Read it in the 10-K ↗

“3M is the sole source of supply for certain chemical materials and inputs used in our products (including transparent IV film dressings, biological indicators for sterilization assurance, medical securement tapes and dental composites and cements) that, as of the Spin-Off, accounted for approximately $3 billion of our revenue for fiscal year 2025, including a material with a manufacturing process proprietary to 3M that is used in our products accounting for approximately $2 billion of our revenue for fiscal year 2025.”

Read it in the 10-K ↗

Pending cases, settlements and what the company has set aside for them.

“Such requests can also lead to the assertion of claims or the commencement of administrative, civil, or criminal legal proceedings against Solventum and others, as well as to settlements.”

Read it in the 10-K ↗

“Many lawsuits and claims involve highly complex issues relating to causation, scientific evidence, and alleged actual damages, all of which are otherwise subject to substantial uncertainties.”

Read it in the 10-K ↗

“As a result, the current accruals and/or estimates of loss and the estimates of the potential impact on the Company’s consolidated financial position, results of operations and cash flows for the legal proceedings and claims pending against the Company will likely change over time.”

Read it in the 10-K ↗

“During 2025 and 2024, the Company made payments of $16 million and $6 million, respectively, related to a legal settlement, which reduced the accrued litigation balance.”

Read it in the 10-K ↗

“At December 31, 2025 and December 31, 2024, accrued litigation costs were $31 million and $25 million, respectively.”

Read it in the 10-K ↗

Promises to pay someone else's debts or losses if they cannot.

“The Company had approximately $82 million in bank guarantees, surety bonds, and other similar instruments issued and outstanding at December 31, 2025.”

Read it in the 10-K ↗

“The Company had approximately $82 million and $40 million in bank guarantees, surety bonds, and other similar instruments issued and outstanding at December 31, 2025 and 2024, respectively.”

Read it in the 10-K ↗

Conditions in loan agreements that, if broken, can make debt due early.

New “The Company is in compliance with all covenants related to the Senior Notes.”

Read it in the 10-K ↗

Contracts the company must pay for later: purchase obligations, take-or-pay deals.

New “As of December 31, 2025, unconditional purchase obligations aggregated to approximately $330 million over the next five years, primarily comprised of IT-related obligations.”

Read it in the 10-K ↗